Aerts Austin sold $4K of SERA

Aerts Austin (Chief Financial Officer) sold 2,037 shares of SERA PROGNOSTICS, INC. (SERA) at $2.01 on 2026-06-11.

Original reporting
SEC EDGAR · Aerts Austin
Published Jun 15, 2026, 8:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 15, 2026, 8:26 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SERA
Neutral
high confidence
Mentioned
$SERA
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SERANeutralLow
01

Why it matters

The newest fact is the CFO’s open-market sale details (shares, price, total value, post-transaction holdings). This can modestly influence retail sentiment but lacks accompanying company fundamentals in the provided text.

02

Market read

Traders may monitor for follow-on insider activity or unusual selling patterns, but the disclosure alone is unlikely to drive a major repricing.

03

What to watch

The article does not state whether the sale was part of a broader pattern, tax event, or diversification; it also notes no pre-arranged 10b5-1 plan, which could increase interpretive uncertainty.

Relevance 3/10Novelty 6/10Timing: Filed 2026-06-15; sale executed 2026-06-11

Background

The article is an SEC Form 4 insider transaction disclosure for SERA PROGNOSTICS, INC.

Company-level read

Ticker impact

$SERANeutralHigh confidence
Context

CFO Aerts Austin filed an open-market sale of 2,037 SERA shares at $2.01 on 2026-06-11, per SEC Form 4.

Expected impact

Low near-term impact; any effect is likely sentiment-driven and short-lived unless followed by additional disclosures.

Evidence & confidence

The filing is an insider open-market sale with no 10b5-1 plan stated and no accompanying company-specific operational/regulatory news in the text.

Market effects

No sector-level read-through; this is a single-company insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Insider sales can be planned for liquidity/tax and may not reflect bearish fundamentals, especially when the transaction is small relative to typical insider holdings.

Key entities

  • SERA PROGNOSTICS, INC.

    Subject of the SEC Form 4 insider transaction; CFO sold shares in an open-market sale.

  • Aerts Austin

    Chief Financial Officer who executed the reported sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$SERAMed

SERA PROGNOSTICS REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS

SERA PROGNOSTICS, INC. (SERA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SERA PROGNOSTICS REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS Company Drives Significant Increases in Test Volume and Ordering Providers with Florida Becoming Second Medicaid State Covering Test • PreTRM® test volume increases 54% sequentially and approximately five-

$SERAMed

Sera (SERA) Q2 2026 Earnings Call Transcript

Sera Prognostics (SERA) reported Q2 2026 revenue of $30,000, up from $17,000 last year, with a net loss of $9.1 million. The company exceeded its payer engagement goal, reaching over 20 states, and launched four commercial partnership programs. Clinical data showed a 22% reduction in NICU admissions and a 30% reduction in neonatal morbidity among first-time mothers. Management expects cash to fund operations through 2029.

$SERAMed

SERA PROGNOSTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS

Sera Prognostics (Nasdaq: SERA) reported Q2 2026 revenue of $30,000 versus $17,000 in Q2 2025, with operating expenses of $10.0 million and a net loss of $9.1 million. The company said Illinois Medicaid coverage for PreTRM proteomic tests expanded, it launched a fourth payer partnership program, and PRIME trial data showed reduced NICU admissions in first-time mothers. Cash was about $80.3 million.

$SERAMed

SERA PROGNOSTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS

SERA PROGNOSTICS, INC. (SERA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SERA PROGNOSTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS Salt Lake City – August 12, 2026 – Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information t